Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.

Humans Interleukin-6 / immunology Neuromyelitis Optica / drug therapy Receptors, Interleukin-6 / antagonists & inhibitors

Journal

Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388

Informations de publication

Date de publication:
03 09 2020
Historique:
received: 01 04 2020
accepted: 05 06 2020
entrez: 22 8 2020
pubmed: 21 8 2020
medline: 14 9 2021
Statut: epublish

Résumé

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disorder that preferentially affects the spinal cord and optic nerve. Most patients with NMOSD experience severe relapses that lead to permanent neurologic disability; therefore, limiting frequency and severity of these attacks is the primary goal of disease management. Currently, patients are treated with immunosuppressants. Interleukin-6 (IL-6) is a pleiotropic cytokine that is significantly elevated in the serum and the CSF of patients with NMOSD. IL-6 may have multiple roles in NMOSD pathophysiology by promoting plasmablast survival, stimulating the production of antibodies against aquaporin-4, disrupting blood-brain barrier integrity and functionality, and enhancing proinflammatory T-lymphocyte differentiation and activation. Case series have shown decreased relapse rates following IL-6 receptor (IL-6R) blockade in patients with NMOSD, and 2 recent phase 3 randomized controlled trials confirmed that IL-6R inhibition reduces the risk of relapses in NMOSD. As such, inhibition of IL-6 activity represents a promising emerging therapy for the management of NMOSD manifestations. In this review, we summarize the role of IL-6 in the context of NMOSD.

Identifiants

DOI: 10.1212/NXI.0000000000000841 PMID: 32820020 PMC: PMC7455314
pubmed: 32820020
pii: 7/5/e841
doi: 10.1212/NXI.0000000000000841
pmc: PMC7455314
pii:
doi:

Substances chimiques

IL6 protein, human 0
IL6R protein, human 0
Interleukin-6 0
Receptors, Interleukin-6 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NEI NIH HHS
ID : R01 EY022936
Pays : United States

Informations de copyright

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

Neurology. 2014 Apr 15;82(15):1302-6
pubmed: 24634453
Mod Rheumatol. 2013 Jul;23(4):827-31
pubmed: 22782533
Ann Neurol. 2009 Nov;66(5):617-29
pubmed: 19938104
Neurol Neuroimmunol Neuroinflamm. 2018 Jun 07;5(4):e468
pubmed: 29892608
Lancet. 2004 Dec 11-17;364(9451):2106-12
pubmed: 15589308
BMJ Case Rep. 2014 Mar 26;2014:
pubmed: 24671322
Mult Scler. 2015 Aug;21(9):1204-8
pubmed: 25480860
N Engl J Med. 2019 Aug 15;381(7):614-625
pubmed: 31050279
BMC Neurol. 2014 Dec 17;14:247
pubmed: 25516429
FASEB J. 2015 May;29(5):1739-53
pubmed: 25609424
Acta Neuropathol. 2017 Jul;134(1):35-44
pubmed: 28567523
PLoS One. 2013 Apr 18;8(4):e61835
pubmed: 23637915
Clin Chim Acta. 2017 Jun;469:144-149
pubmed: 28283439
J Neurol. 2009 Dec;256(12):2082-4
pubmed: 19655191
JAMA Neurol. 2015 Jul;72(7):756-63
pubmed: 25985228
Clin Chim Acta. 2013 Jun 5;421:181-3
pubmed: 23535508
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Neuroimmunomodulation. 2012;19(5):304-8
pubmed: 22777162
Mediators Inflamm. 2016;2016:5314541
pubmed: 26941483
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Neurol Neuroimmunol Neuroinflamm. 2016 Dec 19;4(1):e311
pubmed: 28018943
J Exp Med. 2009 Jan 16;206(1):69-78
pubmed: 19139170
Exp Ther Med. 2015 May;9(5):1695-1701
pubmed: 26136879
J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1257-1259
pubmed: 26800711
Nat Rev Drug Discov. 2018 Jun;17(6):395-412
pubmed: 29725131
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):339-40
pubmed: 21429904
Acta Neuropathol Commun. 2019 Jul 11;7(1):112
pubmed: 31296268
Front Immunol. 2015 Dec 17;6:639
pubmed: 26734006
Acta Neuropathol Commun. 2017 Jul 27;5(1):57
pubmed: 28750658
Int J Neurosci. 2010 Jan;120(1):71-5
pubmed: 20128675
Neurol Neuroimmunol Neuroinflamm. 2015 May 21;2(4):e110
pubmed: 26185772
Biochim Biophys Acta. 2014 May;1840(5):1492-506
pubmed: 24090884
Ann Clin Transl Neurol. 2017 May 09;4(6):369-380
pubmed: 28589164
Lancet Neurol. 2007 Sep;6(9):805-15
pubmed: 17706564
Mult Scler. 2017 Jul;23(8):1072-1084
pubmed: 27682231
Brain. 2012 Jun;135(Pt 6):1834-49
pubmed: 22577216
Ann N Y Acad Sci. 2013 Apr;1283:57-66
pubmed: 23617588
N Engl J Med. 2019 Nov 28;381(22):2114-2124
pubmed: 31774956
J Neuroimmunol. 2014 Sep 15;274(1-2):185-91
pubmed: 25109258
Lancet. 2019 Oct 12;394(10206):1352-1363
pubmed: 31495497
JAMA Neurol. 2013 Mar 1;70(3):394-7
pubmed: 23358868
Mult Scler. 2010 Dec;16(12):1443-52
pubmed: 20739337
Neurology. 2006 May 23;66(10):1485-9
pubmed: 16717206
Lancet Neurol. 2020 May;19(5):402-412
pubmed: 32333898
Int J Biol Sci. 2012;8(9):1254-66
pubmed: 23136554
Clin Exp Immunol. 2016 Mar;183(3):480-9
pubmed: 26472479
Neurotherapeutics. 2018 Jan;15(1):92-101
pubmed: 29280091
Sci Transl Med. 2017 Jul 5;9(397):
pubmed: 28679661
J Neuroinflammation. 2012 Jan 19;9:14
pubmed: 22260418
J Neuroinflammation. 2015 Jan 28;12:19
pubmed: 25626447
JAMA Neurol. 2013 Mar 1;70(3):390-3
pubmed: 23599943
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3701-6
pubmed: 21321193
Mayo Clin Proc. 2017 Apr;92(4):663-679
pubmed: 28385199
Ann Neurol. 2012 Jul;72(1):53-64
pubmed: 22807325
J Clin Neurosci. 2011 Oct;18(10):1313-7
pubmed: 21795048
Int J Biol Sci. 2012;8(9):1227-36
pubmed: 23136551
Cytokine Growth Factor Rev. 2013 Apr;24(2):163-73
pubmed: 23107589
Nat Rev Neurol. 2014 Sep;10(9):493-506
pubmed: 25112508
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
J Neuroinflammation. 2010 Sep 08;7:52
pubmed: 20825655

Auteurs

Kazuo Fujihara (K)

From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan. fujikazu@med.tohoku.ac.jp.

Jeffrey L Bennett (JL)

From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Jerome de Seze (J)

From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Masayuki Haramura (M)

From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Ingo Kleiter (I)

From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
ORCID: 0000-0002-8249-4408

Brian G Weinshenker (BG)

From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
ORCID: 0000-0001-5806-6203

Delene Kang (D)

From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Tabasum Mughal (T)

From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Takashi Yamamura (T)

From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Interleukin-6 in neuromyelitis optica spectrum...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-6 › Interleukin-6 in neuromyelitis optica spectrum...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Neuromyélite optique › Interleukin-6 in neuromyelitis optica spectrum...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux cytokines › Récepteurs aux interleukines › Récepteurs à l'interleukine-6 › Interleukin-6 in neuromyelitis optica spectrum...